MedTrace Logo

Treatment of AA Amyloidosis

NCT06397001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-02-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.

Conditions

  • AA Amyloidosis

Interventions

DRUG

nL-SAA1-01

Personalized antisense oligonucleotide

Sponsors & Collaborators

  • Nelson Leung, MD

    lead OTHER

Principal Investigators

  • Nelson Leung, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2024-12-02
Completion
2024-12-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06397001 on ClinicalTrials.gov